ReviewWorld journal of surgical oncology2025
Historical evolution and current research status of lymph node staging in gastric cancer: a review.
Review in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- LAMB3 drives gastric cancer progression through SAMD4A-mediated degradation of PHLPP2 mRNA leading to sustained PI3K-Akt activation.British journal of cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Lymph node metastasis (LNM) is an independent prognostic factor for patients with gastric cancer (GC), and an accurate lymph node (LN) staging system is crucial for guiding adjuvant therapy and assessing patient prognosis. The most commonly used staging systems for GC are the tumor-node-metastasis (TNM) system developed by the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC), as well as the Japanese classification system. The N staging system in both classification methods has undergone multiple revisions and improvements. Early versions classified N stage based on the distance between the tumor margin and metastatic LNs. Over time, this shifted to a system based on the number of metastatic LNs, significantly improving staging precision. To further enhance the accuracy of N staging, the researchers have introduced new concepts such as the metastatic lymph nodes ratio (LNR), the log odds of positive lymph nodes (LODDS), and the negative lymph node count (NLNC). These new parameters have demonstrated better prognostic accuracy than the eighth edition of the UICC/AJCC N staging system. In addition, artificial intelligence (AI) has emerged as a rapidly evolving domain, demonstrating exponential growth in algorithmic sophistication and computational applications. Machine learning (ML) models and deep learning (DL) models have demonstrated superior performance in assessing LNM, aiding in staging, and predicting prognosis in GC. This review provides a systematic overview of the historical evolution, current practices, and recent innovations in GC lymph node staging, aiming to inform the development of next-generation prognostic frameworks.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.